Slide 1: Exchange filing cover letter for Q3 FY24 results presentation
February 01, 2024 The National Stock Exchange of India Limited BSE Limited Exchange Plaza Phiroze Jeejeeboy Towers Bandra Kurla Complex, Dalal Street, Bandra (E), Mumbai - 400 051 Mumbai- 400 001 (SYMBOL: THYROCARE) (SCRIP CODE 539871) Dear Sirs/Madam, Sub: Presentation- unaudited financial results
Slide 2: Thyrocare Earnings Presentation Q3 FY24
S Thyrocare Tests you can trust Thyrocare Earnings Presentation Q3 FY24
Slide 3: Safe harbour statement
Safe harbour statement Statements in this presentation describing the Company’s performance may be “forward looking statements” within the meaning of applicable securities laws and regulations. Actual results may differ materially from those directly or indirectly expressed, inferred or implied.Impo
Slide 4: Agenda
Agenda ie What Is Keeping Us Busy 02 Performance Highlights 03 Financial Performance 04 Going Forward Strategy 02
Slide 5: What is keeping us busy
➢ Lab setup in Tanzania underway ➢ Impetus on developing new brands: ➢ Onboarded new clients in and will be completed before end of Jaanch (Investigative) and Hercheck Healthtech and Insurance segments this FY (Women’s care) ➢ Execution of SPA for acquisition of ➢ Plan to target hospitals and ➢ Prom
Slide 6: Agenda: Performance Highlights
Agenda 01 What Is Keeping Us Busy ya Performance Highlights 03 Financial Performance 04 Going Forward Strategy 04
Slide 7: Performance highlights
+5% Radiology** +5% +9% +3% 26% ** Radiology includes Pulse Hi-Tech 5
Slide 8: Pathology and radiology revenue trend
5% 3% +5% +3% 148.0 42.5 40.3 41.7 135.9 134.9 134.7 35.3 128.0 34.2 1.4 1.1 11.7 1.6 11.1 11.3 11.9 2.0 1.0 10.9 38.7 40.3 41.5 32.3 34.3 124.8 136.3 117.2 123.6 122.9 Q3FY23 Q4FY23 Q1FY24 Q2FY24 Q3FY24 Q3FY23 Q4FY23 Q1FY24 Q2FY24 Q3FY24 Pathology Radiology (Inc pulse hitech) Pathology Radiology (I
Slide 9: Revenue by channel: franchise and partnerships
11% 33% +11% +1% +33% +8% 110 cr 119 cr 119 cr 131 cr 119 cr +8% 54 L 57 L 54 L 58 L 51 L 7 Pathology excludes materials and others.
Slide 10: Agenda: Financial Performance
Agenda 01 What Is Keeping Us Busy 02 Performance Highlights (KE Financial Performance 04 Going Forward Strategy 08
Slide 11: Pathology revenue grew 5% YoY, Franchise 11%
Quarter Growth % INR crore Q3FY24 Q2FY24 Q3FY23 Seq. YOY Pathology revenue grew by 5% YoY, Revenue from operations 122.9 136.3 117.2 -10% 5% while the Franchise grew by 11%; Cost of materials consumed/sold (36.4) (41.3) (39.0) -12% -7% Partnerships (excluding API & B2G) Gross margin 86.5 95.0 78.2 -
Slide 12: NHL revenue decreased 6% YoY
Quarter Growth % INR crore Q3FY24 Q2FY24 Q3FY23 Seq. YOY NHL Revenue decreased 6% YoY on Revenue from operations 10.2 10.7 10.9 -5% -6% account of machine breakdown and low (1.8) (2.3) (1.8) -23% -4% Cost of materials consumed/sold yield. Gross margin 8.4 8.4 9.0 0% -6% Employee benefit expenses (1.
Slide 13: Consolidated financials
Quarter Growth % INR crore Q3FY24 Q2FY24 Q3FY23 Seq. YOY Revenue from operations includes Pulse -9% 5% Revenue from operations 134.7 148.0 128.0 Hitech. Lower yield in QoQ revenue Cost of materials consumed/sold (38.4) (43.6) (40.9) -12% -6% mainly due to festivity. Gross margin 96.3 104.4 87.2 -8%
Slide 14: Agenda: Going Forward Strategy
Agenda 01 What Is Keeping Us Busy 02 Performance Highlights 03 ‘Financial Performance Going Forward Strategy 12
Slide 15: Vision & Mission
Vision & Mission Mission Global in our reach, excellence in our experience To ensure everyone has access to quality & affordable diagnostics 13
Slide 16: Our strategy remains to be a B2B service provider
Our strategy remains to be a B2B service provider with an affordable value driven model based on scale efficiencies 4G Thyrocare Tests you can trust Franchise Partnership +B2G > Mom & Pop collection centers > Online diagnostics aggregators > Local labs > Healthcare platforms > Nursing homes & hospit
Slide 17: Going forward - Key pillars of growth
Going forward - Key pillars of growth Public & Private Franchise Partnerships > Going deeper into India with > Focus on TB and Infectious focused test menu Disease along with large screening programs run by Health bodies and Funding agencies > Strengthening our existing Franchise network with focus
Slide 18: Thank You
Q Thyrocare Tests you can trust For Any queries, please reach out to investor_relations@thyrocare.com Thank You Disclaimer This presentation is for information purposes only and it contains general background information about the Company’s activities. The Company assumes no responsibility to public